Biology:ALLO-715
ALLO-715 is a CAR-T therapy by Allogene Therapeutics that targets B-cell maturation antigen (BCMA).[1] (As of June 2021), it is undergoing clinical trials for the treatment of multiple myeloma.[2] On 21 April 2021, Allogene Therapeutics announced that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy status to ALLO-715.[3]
Medical uses
CAR-T therapies target a patient's own T cells to respond to a particular antigen. Most CAR-T therapies on the market are autologous, that is, they rely on cells extracted from the patient, processed and reinfused.[4] Tisagenlecleucel (Kymriah), for instance, is made by extracting the patient's blood, filtering T cells and processing them.[5] Allogeneic CAR-T therapies may be able to dispense with this process through using TALEN gene editing technology and using T cells from healthy donors, obtained by leukapheresis. ALLO-715 is being investigated at Memorial Sloan Kettering Cancer Center and the Mayo Clinic[6] as part of the UNIVERSAL trial for multiple myeloma, on its own and in conjunction with the selective gamma secretase inhibitor nirogacestat.[2] Initial results of the UNIVERSAL trial were reported in late 2020 to be promising.[7]
References
- ↑ Sommer, Cesar; Boldajipour, Bijan; Valton, Julien; Galetto, Roman; Bentley, Trevor; Sutton, Janette; Ni, Yajin; Leonard, Mark et al. (2018-11-29). "ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma". Blood 132 (Supplement 1): 591. doi:10.1182/blood-2018-99-119227. ISSN 0006-4971.
- ↑ 2.0 2.1 Allogene Therapeutics (2021-06-23). A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT04093596.
- ↑ "FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma" (in en). https://www.onclive.com/view/fda-grants-rmat-designation-to-allo-715-for-relapsed-refractory-multiple-myeloma.
- ↑ Manier, Salomon; Ingegnere, Tiziano; Escure, Guillaume; Prodhomme, Chloé; Nudel, Morgane; Mitra, Suman; Facon, Thierry (2022-01-21). "Current state and next-generation CAR-T cells in multiple myeloma" (in en). Blood Reviews 54: 100929. doi:10.1016/j.blre.2022.100929. ISSN 0268-960X. PMID 35131139. https://www.sciencedirect.com/science/article/pii/S0268960X22000030.
- ↑ Ledford, Heidi (2017-07-01). "Engineered cell therapy for cancer gets thumbs up from FDA advisers" (in en). Nature 547 (7663): 270. doi:10.1038/nature.2017.22304. ISSN 1476-4687. PMID 28726836. Bibcode: 2017Natur.547..270L.
- ↑ "Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)" (in en). https://www.mayo.edu/research/clinical-trials/cls-20484366.
- ↑ Taylor, Nick Paul (2020-12-07). "ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field" (in en). https://www.fiercebiotech.com/biotech/ash-allogene-s-off-shelf-car-t-posts-60-response-rate-fiercely-competitive-bcma-field.
 |
